Search for other papers by Yurong Lu in
Google Scholar
PubMed
Search for other papers by Yuqing Zhao in
Google Scholar
PubMed
Search for other papers by Penggang Liu in
Google Scholar
PubMed
Joint International Research Laboratory of Agriculture and Agri-Product Safety of Ministry of Education of China, Yangzhou, Jiangsu Province, China
Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, Jiangsu Province, China
Search for other papers by Xiulong Xu in
Google Scholar
PubMed
B-Raf kinase inhibitors such as vemurafenib (PLX4032) and dabrafenib have limited therapeutic efficacy on BRAF-mutated thyroid cancer. Cancer stem cells (CSCs) play important roles in tumor recurrence, drug resistance, and metastasis. Whether CSCs play a role in dampening the antitumor activity of B-Raf kinase inhibitors remains unknown. Here, we report that vemurafenib (PLX4032) induced the expression of several stemness-related genes including Gli1, Snail, BMI1, and SOX2 in two anaplastic thyroid cancer cell lines, SW1736 and 8505C, but decreased the expression of these genes in A375 cells, a human melanoma cell line. PLX4032 promoted thyroid cancer stem cell self-renewal, as evidenced by increased numbers of aldehyde dehydrogenase-positive cells and thyrospheres. Mechanistically, PLX4032 activates the PI-3 and mitogen-activated protein kinase pathways through HER3 to cross-activate Gli1, a transcription factor of the sonic hedgehog (Shh) pathway. GANT61, a specific inhibitor of Gli1, blocked the expression of the stemness-related genes in PLX4032-treated thyroid cancer cells in vitro and in vivo in two thyroid cancer xenograft models. GANT61 treatment alone weakly inhibited SW1736 tumor growth but enhanced the antitumor activity of PLX4032 when used in combination. Our study provides mechanistic insights into how thyroid cancer poorly responds to B-Raf kinase inhibitors and suggests that targeting B-Raf and the Shh pathway in combination may overcome thyroid cancer drug resistance.
Search for other papers by Francesca Amore in
Google Scholar
PubMed
Search for other papers by Rachele Garella in
Google Scholar
PubMed
Search for other papers by Alice Santi in
Google Scholar
PubMed
Search for other papers by Daniele Guasti in
Google Scholar
PubMed
Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, Florence, Italy
ENS@T Center of Excellence, Florence, Italy
Search for other papers by Serena Martinelli in
Google Scholar
PubMed
Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, Florence, Italy
ENS@T Center of Excellence, Florence, Italy
Search for other papers by Letizia Canu in
Google Scholar
PubMed
Search for other papers by Daniele Bani in
Google Scholar
PubMed
School of Pharmacy and Medical Science, Griffith University, Southport, Queensland, Australia
Faculty of Science and 1st Medical Faculty, Charles University, Prague, Czech Republic
Search for other papers by Jiri Neuzil in
Google Scholar
PubMed
Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, Florence, Italy
ENS@T Center of Excellence, Florence, Italy
Search for other papers by Mario Maggi in
Google Scholar
PubMed
Search for other papers by Roberta Squecco in
Google Scholar
PubMed
Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, Florence, Italy
ENS@T Center of Excellence, Florence, Italy
Search for other papers by Elena Rapizzi in
Google Scholar
PubMed
Pheochromocytomas/paragangliomas (PPGLs) are neuroendocrine tumours, mostly resulting from mutations in predisposing genes. Mutations of succinate dehydrogenase (SDH) subunit B (SDHB) are associated with high probability of metastatic disease. Since bioelectrical properties and signalling in cancer are an emerging field, we investigated the metabolic, functional and electrophysiological characteristics in human succinate dehydrogenase subunit B (SDHB)-deficient pheochromocytoma cells. These cells exhibited reduced SDH function with elevated succinate-to-fumarate ratio and reduced intracellular ATP levels. The analysis of membrane passive properties revealed a more hyperpolarized membrane potential and a lower cell capacitance of SDHB-deficient cells compared to the parental ones. These bioelectrical changes were associated with reduced proliferation and adhesion capacity of SDHB-deficient cells. Only in SDHB-deficient cells, we also observed an increased amplitude of potassium currents suggesting an activation of ATP-sensitive potassium channels (KATP). Indeed, exposure of the SDHB-deficient cells to glibenclamide, a specific KATP inhibitor, or to ATP caused normalization of potassium current features and altered proliferation and adhesion. In this work, we show for the first time that reduced intracellular ATP levels in SDHB-deficient chromaffin cells impaired cell bioelectrical properties, which, in turn, are associated with an increased cell aggressiveness. Moreover, we first ever demonstrated that glibenclamide not only reduced the outward potassium currents in SDHB-deficient cells but increased their growth capacity, reduced their ability to migrate and shifted their phenotype towards one more similar to that of parental one.
Instituto de Endocrinología IEMYR, Quito, Ecuador
Maastricht University, Maastricht, The Netherlands
Search for other papers by Jaime Guevara-Aguirre in
Google Scholar
PubMed
Search for other papers by Gabriela Peña in
Google Scholar
PubMed
Search for other papers by William Acosta in
Google Scholar
PubMed
Search for other papers by Gabriel Pazmiño in
Google Scholar
PubMed
Search for other papers by Jannette Saavedra in
Google Scholar
PubMed
Search for other papers by Lina Soto in
Google Scholar
PubMed
Search for other papers by Daniela Lescano in
Google Scholar
PubMed
Search for other papers by Alexandra Guevara in
Google Scholar
PubMed
Search for other papers by Antonio W D Gavilanes in
Google Scholar
PubMed
The relationship between growth hormone (GH) excess and cancer is a controversial matter. Until 2016, most studies in patients with acromegaly found links with colon and thyroid neoplasms. However, recent studies found increased risks in gastric, breast, and urinary tract cancer also. Concordantly, clinical situations where GH and insulin-like growth facto-I deficits exist are indeed associated with diminished malignancy incidence. In line with these observations, gain-of-function mutations of various enzymes belonging to the GH and IGF-I signaling pathways have been associated with increased carcinogenesis; similarly, loss-of-function mutations of other enzymes that usually work as tumor repressors are also associated with augmented cancer risk. In a study performed in Ecuador, it was demonstrated that subjects in the Ecuadorian cohort with Laron syndrome (ELS), who have a mutant GH receptor and greatly diminished GH and IGF-I signaling, display diminished incidence of cancer. Along with absent action of GH and IGF-I, ELS individuals also have low serum insulin levels and decreased insulin resistance. Furthermore, hyperglycemia and hyperinsulinemia are indispensable for fast cell mitosis, including that of those cells present in the benign and malignant neoplasms. Notably, and despite their obesity, subjects with the ELS display normoglycemia and hypo-insulinemia, along with diminished incidence of malignancies. We believe that the dual low-IGF-I/low insulin serum levels are responsible for the cancer protection, especially considering that the insulin/INSR signaling is a central site for energy generation in the form of ATP and GDP, which are indispensable for all and every GH/IGF-I physiologic as well as pathologic events.
Search for other papers by Meggie M C M Drissen in
Google Scholar
PubMed
Search for other papers by Janet R Vos in
Google Scholar
PubMed
Search for other papers by Romana T Netea-Maier in
Google Scholar
PubMed
Search for other papers by Martin Gotthardt in
Google Scholar
PubMed
Search for other papers by Nicoline Hoogerbrugge in
Google Scholar
PubMed
Thyroid cancer surveillance (TCS) with ultrasound (US) is advised for PTEN hamartoma tumour syndrome (PHTS) patients due to increased thyroid cancer (TC) risk. However, data supporting TCS guidelines are scarce. We aimed to assess the detection and yield of annual TCS with US in adult PHTS patients without a TC history and to evaluate the impact of a reduced US interval on the TCS yield. A retrospective cohort study was conducted, including adult PHTS patients and medical record data between 2005 and 2021. The yield from annual TCS was compared with hypothetical biennial and triennial TCS after two initial US with annual interval by counting delayed detection of nodular growth, thyroid adenoma, and TC. During 279 follow-up years, 84 patients (median age 40 years) underwent 349 US. Thyroidectomy was performed in 6/84 (7%) patients, revealing a minimally invasive follicular TC in one patient aged 22 and a thyroid adenoma in two patients aged 21 and 53. Multiple thyroid nodules were diagnosed in 73/84 (87%) patients (median age 36 years). Nodular growth was detected in 9/56 (16%) patients, and its detection would have been delayed in 4–7% US rounds with biennial TCS, and in 2–6% US rounds with triennial TCS. US-based thyroiditis and indeterminate non-malignant lymph nodes were found in 8/74 (11%) and 7/72 (10%) patients, respectively. Following our findings combined with the literature, we propose starting TCS before age 18 and reducing the follow-up frequency after the initial two US from annual to biennial if no suspicious findings are detected.
Division of Pulmonary and Critical Care Medicine, Asante Health System, Medford, Oregon, USA
Search for other papers by Bilal F Samhouri in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Search for other papers by Chi Wan Koo in
Google Scholar
PubMed
Department of Respiratory Medicine, St Vincent’s University Hospital, Elm Park, Dublin, Ireland
Search for other papers by Cormac McCarthy in
Google Scholar
PubMed
Search for other papers by Eunhee S Yi in
Google Scholar
PubMed
Search for other papers by Charles F Thomas in
Google Scholar
PubMed
Search for other papers by Jay H Ryu in
Google Scholar
PubMed
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare, but increasingly recognized entity that primarily affects middle-aged and elderly women. It is characterized by abnormal proliferation of pulmonary neuroendocrine cells (PNECs) and is considered a preinvasive lesion for carcinoid tumorlets/tumors. Sometimes, DIPNECH is accompanied by constrictive bronchiolitis which usually manifests as chronic cough and/or dyspnea, along with airflow limitation on spirometry. The telltale imaging sign of DIPNECH is the presence of multiple noncalcified pulmonary nodules and mosaic attenuation on CT. However, these clinico-radiologic features of DIPNECH are characteristic but nonspecific; thus, histopathologic confirmation is usually necessary. DIPNECH has an indolent course and only rarely leads to respiratory failure or death; progression to overt neuroendocrine tumor (carcinoid) of the lung occurs in a minority of patients. Of available therapies, somatostatin analogs and mechanistic target of rapamycin inhibitors are the most promising. In this review, we provide an update regarding the diagnosis and management of DIPNECH and describe critical gaps in our understanding of this entity, including the central terms ‘diffuse’ and ‘idiopathic.’ We also summarize the inconsistencies in definitions employed by recent studies and discuss the pitfalls of the DIPNECH definitions proposed by the World Health Organization in 2021. In this context, we propose an objective and reproducible radio-pathologic case definition intended for implementation in the research realm and seeks to enhance homogeneity across cohorts. Furthermore, we discuss aspects of PNECs biology which suggest that PNEC hyperplasia may contribute to the pathogenesis of phenotypes of lung disease aside from constrictive bronchiolitis and carcinoid tumorlets/tumors. Finally, we steer attention to some of the most pressing and impactful research questions awaiting to be unraveled.
Search for other papers by Fabio R Faucz in
Google Scholar
PubMed
Search for other papers by Anelia D Horvath in
Google Scholar
PubMed
Endocrine Department, Center for Rare Adrenal Diseases, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Guillaume Assié in
Google Scholar
PubMed
Adrenal Unit, Laboratory of Molecular and Cellular Endocrinology LIM/25, Division of Endocrinology and Metabolism, University of Sao Paulo Medical School, São Paulo, Brasil
Search for other papers by Madson Q Almeida in
Google Scholar
PubMed
Search for other papers by Eva Szarek in
Google Scholar
PubMed
Search for other papers by Sosipatros Boikos in
Google Scholar
PubMed
Search for other papers by Anna Angelousi in
Google Scholar
PubMed
Search for other papers by Isaac Levy in
Google Scholar
PubMed
Search for other papers by Andrea G Maria in
Google Scholar
PubMed
Search for other papers by Ajay Chitnis in
Google Scholar
PubMed
Search for other papers by Cristina R Antonescu in
Google Scholar
PubMed
Search for other papers by Rainer Claus in
Google Scholar
PubMed
Endocrine Department, Center for Rare Adrenal Diseases, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed
Search for other papers by Christoph Plass in
Google Scholar
PubMed
Search for other papers by Charis Eng in
Google Scholar
PubMed
Human Genetics & Precision Medicine, IMBB, Foundation for Research & Technology Hellas, Heraklion, Crete, Greece
Research Institute, ELPEN, Pikermi, Athens, Greece
Search for other papers by Constantine A Stratakis in
Google Scholar
PubMed
Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms, believed to originate from the interstitial cells of Cajal (ICC), often caused by overexpression of tyrosine kinase receptors (TKR) KIT or PDGFRA. Here, we present evidence that the embryonic stem cell factor FOXD3, first identified as ‘Genesis’ and involved in both gastrointestinal and neural crest cell development, is implicated in GIST pathogenesis; its involvement is investigated both in vitro and in zebrafish and a mouse model of FOXD3 deficiency. Samples from a total of 58 patients with wild-type GISTs were used for molecular analyses, including Sanger sequencing, comparative genomic hybridization, and methylation analysis. Immunohistochemistry and western blot evaluation were used to assess FOXD3 expression. Additionally, we conducted in vitro functional studies in tissue samples and in transfected cells to confirm the pathogenicity of the identified genetic variants. Germline partially inactivating FOXD3 sequence variants (p.R54H and p.Ala88_Gly91del) were found in patients with isolated GISTs. Chromosome 1p loss was the most frequent chromosomal abnormality identified in tumors. In vitro experiments demonstrate the impairment of FOXD3 in the presence of those variants. Animal studies showed disruption of the GI neural network and changes in the number and distribution in the ICC. FOXD3 suppresses KIT expression in human cells; its inactivation led to an increase in ICC in zebrafish, as well as mice, providing evidence for a functional link between FOXD3 defects and KIT overexpression leading to GIST formation.
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Andreas Venizelos in
Google Scholar
PubMed
Department of Clinical Science, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
Search for other papers by Hege Elvebakken in
Google Scholar
PubMed
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Search for other papers by Inger Marie B Lothe in
Google Scholar
PubMed
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Geir Olav Hjortland in
Google Scholar
PubMed
Department of Medical Radiation Physics, Lund University, Lund, Sweden
Search for other papers by Anna Sundlöv in
Google Scholar
PubMed
Search for other papers by Johanna Svensson in
Google Scholar
PubMed
Search for other papers by Harrish Garresori in
Google Scholar
PubMed
Search for other papers by Christian Kersten in
Google Scholar
PubMed
Department of Oncology, St. Olavs Hospital, Trondheim, Norway
Search for other papers by Eva Hofsli in
Google Scholar
PubMed
Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Search for other papers by Sönke Detlefsen in
Google Scholar
PubMed
Search for other papers by Lene W Vestermark in
Google Scholar
PubMed
Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by Morten Ladekarl in
Google Scholar
PubMed
Search for other papers by Elizaveta Mitkina Tabaksblat in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Stian Knappskog in
Google Scholar
PubMed
High-grade gastroenteropancreatic (HG-GEP) neuroendocrine neoplasms (NENs) are highly aggressive cancers. The molecular etiology of these tumors remains unclear, and the prevalence of pathogenic germline variants in patients with HG-GEP NENs is unknown. We assessed sequencing data of 360 cancer genes in normal tissue from 240 patients with HG-GEP NENs; 198 patients with neuroendocrine carcinomas (NECs) and 42 with grade 3 neuroendocrine tumors (NET G3). Applying strict criteria, we identified pathogenic germline variants and compared the frequency with previously reported data from 33 different cancer types. We found a recurrent MYOC variant in three patients and a recurrent MUTYH variant in two patients, indicating that these genes may be important underlying risk factors for HG-GEP NENs when mutated. Further, germline variants were found in canonical tumor-suppressor genes, such as TP53, RB1, BRIP1 and BAP1. Overall, we found that 4.5% of patients with NEC and 9.5% of patients with NET G3 carry germline pathogenic or highly likely pathogenic variants. Applying identical criteria for variant classification in silico to mined data from 33 other cancer types, the median percentage of patients carrying pathogenic or highly likely pathogenic variants was 3.4% (range: 0–17%). The patients with NEC and pathogenic germline variants had a median overall survival of 9 months, similar to what is generally expected for metastatic GEP NECs. A patient with NET G3 and pathogenic MUTYH variant had much shorter overall survival than expected. The fraction of HG-GEP NENs with germline pathogenic variants is relatively high, but still <10%, meaning that that germline mutations cannot be the major underlying cause of HG-GEP NENs.
Search for other papers by Christopher A Galifi in
Google Scholar
PubMed
Search for other papers by Teresa L Wood in
Google Scholar
PubMed
Despite decades of research presenting insulin-like growth factor-1 receptor (IGF1R) as an attractive target for cancer therapy, IGF1R inhibitors ultimately failed in clinical trials. This was surprising due to the known cancer-promoting functions of IGF1R, including stimulation of cell invasion, proliferation, and survival. Discourse in the literature has acknowledged that a lack of patient stratification may have impacted the success of IGF1R-inhibitor trials. This argument alludes to the possibility that IGF1R function may be contingent on tumor type and cellular composition. Looking into the known roles of IGF1R, it becomes clear that this receptor interacts with a multitude of different proteins and even has tumor-suppressing functions. IGF1R is implicated in both cell–cell and cell–surface adhesion dynamics, and the effects of either IGF1R downregulation or pharmacological inhibition on cellular adhesion remain poorly understood. In turn, adhesion receptors modulate IGF1R signaling. In addition, our understanding of IGF1R function in tumor-associated immune and stromal cells is lacking, which could contribute to the overwhelming failure of IGF1R inhibitors in the clinic. In this review, we re-investigate clinical trial data to make connections between the failure of these drugs in human cancer patients and the understudied facets of IGF1R function. We describe lesser-known and potentially tumor-suppressive functions of IGF1R that include promoting cell–cell adhesion through E-cadherin, augmenting a pro-inflammatory macrophage phenotype, and stimulating B cells to produce immunoglobulins. We also highlight the important role of adhesion receptors in regulating IGF1R function, and we use this information to infer stratification criteria for selecting patients that might benefit from IGF1R inhibitors.
European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, Florence, Italy
Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, Florence, Italy
Istituto Nazionale Biostrutture e Biosistemi (I.N.B.B.), via delle Medaglie D’Oro, Rome, Italy
Search for other papers by Giulia Cantini in
Google Scholar
PubMed
Search for other papers by Elena Niccolai in
Google Scholar
PubMed
European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, Florence, Italy
Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, Florence, Italy
Search for other papers by Letizia Canu in
Google Scholar
PubMed
Search for other papers by Leandro Di Gloria in
Google Scholar
PubMed
Search for other papers by Simone Baldi in
Google Scholar
PubMed
European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, Florence, Italy
Search for other papers by Arianna Pia Propato in
Google Scholar
PubMed
European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, Florence, Italy
Search for other papers by Laura Fei in
Google Scholar
PubMed
Search for other papers by Giulia Nannini in
Google Scholar
PubMed
Search for other papers by Soraya Puglisi in
Google Scholar
PubMed
Search for other papers by Gabriella Nesi in
Google Scholar
PubMed
Search for other papers by Matteo Ramazzotti in
Google Scholar
PubMed
Search for other papers by Amedeo Amedei in
Google Scholar
PubMed
European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, Florence, Italy
Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, Florence, Italy
Istituto Nazionale Biostrutture e Biosistemi (I.N.B.B.), via delle Medaglie D’Oro, Rome, Italy
Search for other papers by Michaela Luconi in
Google Scholar
PubMed
The infiltrating microbiota represents a novel cellular component of the solid tumour microenvironment that can influence tumour progression and response to therapy. Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy for which mitotane (MTT) treatment represents the first-line therapy, though its efficacy is limited to a therapeutic window level (14–20 mg/L). Novel markers able to predict those patients who would benefit from MTT therapy are urgently needed to improve patient’s management. The aim of our study was to evaluate the presence of intratumoural bacterial microbiota DNA in 26 human ACC tissues vs 9 healthy adrenals; moreover, the association between the relative bacterial composition profile, the tumour mass characteristics and MTT ability to reach high circulating levels in the early phase of treatment, were explored. We found the presence of bacterial DNA in all adrenal samples from both tumours and healthy cortex specimens, documenting significant differences in the microbial composition between malignancy and normal adrenals: in detail, the ACC tissues were characterised by a higher abundance of the Proteobacteria phylum (especially the Pseudomonas and Serratia genera). In addition, the Proteobacteria’s low abundance was negatively associated with tumour size, Ki67 and cortisol secretion. MTT levels reached higher levels at 9 months in ACC patients with high abundance of Proteobacteria, Pseudomonas and Serratia and with low abundance of Bacteroidota, Firmicutes and Streptococcus. These findings are the first indication that human ACCs are characterised by infiltrating bacteria and their specific abundance profile seems to influence the increase in circulating MTT levels at 9 months.
Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy
Search for other papers by Carmine Valenza in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Search for other papers by Francesco Multinu in
Google Scholar
PubMed
Search for other papers by Lavinia Benini in
Google Scholar
PubMed
Search for other papers by Michele Borghesani in
Google Scholar
PubMed
Search for other papers by Laura Algeri in
Google Scholar
PubMed
Search for other papers by Manila Rubino in
Google Scholar
PubMed
Search for other papers by Eleonora Pisa in
Google Scholar
PubMed
Search for other papers by Lorenzo Gervaso in
Google Scholar
PubMed
Search for other papers by Chiara Alessandra Cella in
Google Scholar
PubMed
Search for other papers by Silvestro Carinelli in
Google Scholar
PubMed
Search for other papers by Simone Bruni in
Google Scholar
PubMed
Search for other papers by Gabriella Schivardi in
Google Scholar
PubMed
Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy
Search for other papers by Giuseppe Curigliano in
Google Scholar
PubMed
Search for other papers by Vanna Zanagnolo in
Google Scholar
PubMed
Division of Gynecologic Surgery, European Institute of Oncology, IRCCS, Via Ripamonti, Milan, Italy
Search for other papers by Giovanni Aletti in
Google Scholar
PubMed
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
Search for other papers by Nicoletta Colombo in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Non-metastatic neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive disease. Lacking prospective studies, the optimal multimodal treatment approach has not yet been clearly defined. This study aims to assess the clinical outcomes of patients with non-metastatic NECC treated with surgery and (neo)adjuvant chemotherapy, according to pathologic prognostic factors and multimodal treatments received. We retrospectively examined data from patients with non-metastatic NECC candidate to receive surgery and (neo)adjuvant chemotherapy and discussed at the European Institute of Oncology’s Multidisciplinary Neuroendocrine Tumor Board, between January 2003 and December 2021. Primary endpoints were event-free survival and overall survival. A total of 27 consecutive patients were evaluated, 15 with early stage NECC and 12 with a locally advanced NECC. Eight patients received neoadjuvant and 19 adjuvant platinum-based chemotherapy; 14 received adjuvant pelvic radiotherapy, half with external-beam radiation therapy alone, and half combined with brachytherapy. No patients progressed or relapsed during (neo)adjuvant chemotherapy. The median event-free survival was 21.1 months and the median overall survival was 33.0 months. Pathological FIGO stage ≥ IIB, adjuvant external-beam radiation therapy with or without brachytherapy emerged as significant and independent prognostic factors for event-free survival. Brachytherapy was also prognostic for overall survival. Non-metastatic NECC requires a multimodal approach, mainly weighted on the FIGO stage. The addition of brachytherapy should be considered, especially in patients with locally advanced disease. Because of the scarcity of robust clinical data, treatment strategy should be discussed in multidisciplinary board, taking into account patient.